AHRAmerican Healthcare REIT, Inc.(AHR)Stock Analysis

AI analysis on 2,800+ stocks →
Real EstateNYSE
Institutional-grade research for retail investors
SEC EDGAR: CIK 1632970AHR stock profile & AI dashboard →

13F Pro Quality Score

63.7/100

Rank #674 of 2,879 stocksTOP 25%

View Real Estate peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

70.8/100

Profitability

63.7/100

Balance Sheet

48.4/100

Earnings Quality

30.0/100

Free Cash Flow

72.6/100

Institutional Flow

84.1/100

Revenue Scale

63.7/100

Dilution Risk

68.7/100

AHR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for American Healthcare REIT, Inc. (AHR), a Real Estate sector company. 13F Pro's AI-powered ranking engine scores AHR at 63.7/100 on a 32-signal composite quality model, placing it at rank #674 of 2,879 stocks — the top 25% of the AI-ranked universe. AHR scores in the top quartile across institutional flow (84.1). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), American Healthcare REIT, Inc. reports quarterly revenue of $650.8M, net income of $23.7M, free cash flow of $81.1M. Top institutional holders of AHR by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. AHR trades on the NYSE exchange and files with the SEC under CIK 1632970. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AHR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for American Healthcare REIT, Inc. directly from SEC EDGAR. American Healthcare REIT, Inc.'s 13F Pro composite quality score has ranged between 8 and 72 since 2024, currently 63.7 — an improving long-term trajectory across 43 quarterly and live scoring snapshots.

Revenue

Q1 2026

$650.8M

Net Income

Q1 2026

$23.7M

Free Cash Flow

Q1 2026

$81.1M

ROIC

Q1 2026

3.6%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+32.2% YoY
$1.87BFY 2023
FY20 $1.07BFY21 $1.12BFY22 $1.41BFY23 $1.87B

Net Income

+2.6% YoY
$-71.5MFY 2023
FY20 $2.2MFY21 $-47.8MFY22 $-73.4MFY23 $-71.5M

Operating Income

+1.6% YoY
$306.8MFY 2023
FY20 $218.3MFY21 $213.3MFY22 $302.0MFY23 $306.8M

EPS (Diluted)

+12.9% YoY
$-1.08FY 2023
FY20 $0.05FY21 $-0.95FY22 $-1.24FY23 $-1.08

Total Assets

-4.4% YoY
$4.58BFY 2023
FY20 $3.23BFY21 $4.58BFY22 $4.79BFY23 $4.58B

Op. Cash Flow

-33.3% YoY
$98.5MFY 2023
FY20 $219.2MFY21 $17.9MFY22 $147.8MFY23 $98.5M

AI Insight: AHR Financial Trends

AHR's revenue surged 58% from $411M in Q2 2024 to $651M in Q1 2026, with operating income expanding steadily and net income turning consistently positive from Q2 2025 onward.

Revenue grew from $411M in Q2 2024 to $651M in Q1 2026, an increase of 58% over six quarters.

Operating income expanded from $89M in Q2 2024 to $126M in Q1 2026, reflecting consistent margin improvement.

Net income turned durably positive from Q2 2025 ($10M) through Q1 2026 ($24M), after losses in Q3–Q4 2024.

Equity base grew materially from $1,933M in Q2 2024 to $3,482M in Q1 2026, strengthening the balance sheet.

Operating cash flow dropped sharply to $55M in Q4 2025 from $107M in Q3 2025, a significant sequential decline.

Total debt data is absent across all periods; leverage trajectory remains unassessable and warrants disclosure.

Net income remains volatile quarter-to-quarter ($56M in Q3 2025 vs. $11M in Q4 2025), suggesting non-recurring items.

AI Insight: AHR Ratio Trends

ROIC has contracted nearly 4pp from Q2 2024's 18.4% peak to 14.4% in Q1 2026, even as net margins have recovered from deeply negative territory.

Net margin swung from -6.4% in Q4 2024 to +3.6% in Q1 2026, signaling a meaningful bottom-line recovery over five quarters.

Operating margin has narrowed from 21.6% in Q2 2024 to 19.3% in Q1 2026, a modest but persistent compression.

ROIC declined steadily from 18.4% in Q2 2024 to 13.4% in Q4 2025, with only a partial rebound to 14.4% in Q1 2026.

ROA turned positive at 1.7% in Q1 2026 versus -2.8% in Q4 2024, reflecting improving asset-level profitability.

ROIC at 14.4% in Q1 2026 remains well below the 18.4% peak — sustained contraction would signal capital deployment is becoming less efficient.

The Q3 2025 net margin spike to 9.8% appears one-off; whether normalized earnings can hold above 3% warrants close monitoring.

D/E data is absent across all periods — leverage visibility is zero, a key gap for a capital-intensive REIT.

Get alerted when AHR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for American Healthcare REIT, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of AHR

Put AHR on your watchlist

Track score changes the day American Healthcare REIT, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is AHR a good stock to buy?

13F Pro's AI-powered analysis of American Healthcare REIT, Inc. (AHR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Real Estate sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AHR are available on the AHR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AHR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AHR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of American Healthcare REIT, Inc.'s investment landscape.